- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | HilleVax GAAP EPS of -$0.12 beats by $0.24 | 3 | Seeking Alpha | ||
| 08.05. | HilleVax, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | HilleVax, Inc.: HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress | 213 | GlobeNewswire (Europe) | $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults... ► Artikel lesen | |
| 08.05. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | HilleVax GAAP EPS of -$0.68 misses by $0.35 | 2 | Seeking Alpha | ||
| HILLEVAX Aktie jetzt für 0€ handeln | |||||
| 28.03. | HilleVax, Inc.: HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress | 156 | GlobeNewswire (Europe) | $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults... ► Artikel lesen | |
| 28.03. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.08.24 | HilleVax, Inc.: HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress | 232 | GlobeNewswire (Europe) | $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine... ► Artikel lesen | |
| 31.07.24 | HilleVax, Inc.: HilleVax Announces Reduction in Force | 148 | GlobeNewswire (Europe) | BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce... ► Artikel lesen | |
| 08.07.24 | HilleVax, Inc.: HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants | 350 | GlobeNewswire (Europe) | The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,322 | +0,62 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
| GALAPAGOS NV | 24,420 | +0,25 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new... ► Artikel lesen | |
| CENTOGENE | 0,120 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,310 | -0,32 % | H.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein | ||
| COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
| AC IMMUNE | 1,756 | -1,46 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,338 | +0,34 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| CYTOKINETICS | 28,600 | +0,70 % | Cytokinetics auf der Jefferies-Konferenz: Marktexpansion für Aficamten | ||
| PERSONALIS | 4,682 | +2,32 % | Personalis enthüllt: ctDNA-Test sagt Rückfall bei Gebärmutterhalskrebs voraus | ||
| SPERO THERAPEUTICS | 2,250 | +1,35 % | Why Spero Therapeutics, Inc. (SPRO) Surged Last Week |
HILLEVAX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,990 Euro und damit +1,53 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HILLEVAX INC finden Sie auf Wallstreet Online.